COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222 (COV-COMPARE)
A Randomized, Observer-Blind, Controlled, Superiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine, In Adults Including a Randomized, Observer-blind, Placebo Controlled Part in Adolescents (≥12 to <18 Years)
Sponsor: Valneva Austria GmbH
A PHASE3 clinical study on SARS-CoV-2 Virus Infection, this trial is completed. The trial is conducted by Valneva Austria GmbH and has accumulated 10 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Nov 2021 — Jun 2022 [monthly]
Recruiting PHASE3
Status: Active Not Recruiting → Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Valneva Austria GmbH
For direct contact, visit the study record on ClinicalTrials.gov .